Holen Sie sich die Stockscreener-App
27.40
6.48%
-1.90
Vorhandelsmarkt:
27.21
-0.19
-0.69%
Schlusskurs vom Vortag:
$29.30
Offen:
$29.08
24-Stunden-Volumen:
936.69K
Relative Volume:
1.37
Marktkapitalisierung:
$1.57B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
2.412
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
-10.92%
1M Leistung:
-22.90%
6M Leistung:
-35.48%
1J Leistung:
-5.06%
1-Tages-Spanne:
$26.66
$29.34
1-Wochen-Bereich:
$26.66
$31.15
52-Wochen-Spanne:
$26.66
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
27.40 | 1.57B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Agios stock touches 52-week low at $27.12 amid market shifts - Investing.com
Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
First Week of November 21st Options Trading For Agios Pharmaceuticals (AGIO) - Nasdaq
Agios Pharmaceuticals divulges new PAH stabilizers for phenylketonuria - BioWorld MedTech
Beta Thalassemia Market Predicted to See Upsurge Through 2034, - openPR
Agios Pharmaceuticals at Barclays Conference: Strategic Advances in Rare Disease Treatments - Investing.com UK
Agios Pharm at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com Canada
Q1 EPS Estimate for Agios Pharmaceuticals Lowered by Analyst - Defense World
FY2027 Earnings Estimate for AGIO Issued By Zacks Research - Defense World
Agios Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer - The Manila Times
Agios Pharmaceuticals Announces Inducement Equity Awards for New Executive - GuruFocus.com
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate - EIN News
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences - Barchart
Meet Agios' New Strategy Chief: Inside the $2M+ Executive Compensation Deal - Stock Titan
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock By Investing.com - Investing.com South Africa
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock - Investing.com India
Agios Pharmaceuticals CEO sells shares worth $460,135 - Investing.com
Agios to Present at Upcoming Investor Conferences - The Manila Times
Where to Hear Agios Management Next Month: Key Investor Conferences Revealed - StockTitan
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? - Insider Monkey
Y Intercept Hong Kong Ltd Acquires Shares of 45,817 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
What is HC Wainwright's Estimate for AGIO Q1 Earnings? - MarketBeat
Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises - MSN
10 Best Small-Cap Stocks to Buy Now - Insider Monkey
Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb - MSN
Sickle Cell Disease Market Growth Projections 2024-2034: - openPR
Q4 Earnings Estimate for AGIO Issued By HC Wainwright - MarketBeat
Venturi Wealth Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is HC Wainwright’s Estimate for AGIO Q4 Earnings? - Defense World
Agios Bolsters Coffers With $1.1 Bln Milestone Payments Following FDA Approval Of Vorasidenib - RTTNews
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright starts Agios Pharmaceuticals coverage with 'buy' - TradingView
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating - Investing.com India
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January - MarketBeat
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - The Manila Times
Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem - Simply Wall St
Rare Disease Leader Agios Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to "Sell" - MarketBeat
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues - MSN
Agios Pharmaceuticals (NASDAQ: AGIO) Board Member Resignation: David P. Schenkein Steps Down - Defense World
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates - MSN
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank - Yahoo Finance
Agios Pharmaceuticals announces board resignation - MSN
Long Term Trading Analysis for (AGIO) - Stock Traders Daily
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade) - Seeking Alpha
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):